HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Clinical trial NCT04619004 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04619004
Sponsor: Daiichi Sankyo
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Metastatic Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Start date: 2021-02-02
Primary completion: 2022-11-21
Enrollment: 277

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.